Picture a familiar scenario. Your brand team has six weeks before a major internal review. The question is simple: How are physicians managing your target patient population, and where does your product fit in the real world? The answer would be valuable. But a custom study would often take four to six months, and aligning the budget would take weeks.

So, the team moves forward without existing data. Or they rely on insights that may already be several years old. This isn’t rare. It’s a recurring reality for many pharma insights teams.

And it’s exactly the kind of situation syndicated research was built for.

In short: when syndicated research is the right choice

Choose a syndicated study when:

• You need insights in weeks, not months
• You need market context, not just internal data
• You want to avoid the time and cost of designing and commissioning a new study
• Your team does not have bandwidth for a full custom study
• Multiple functions need the same source of truth

If that sounds familiar, syndicated research is not a fallback. It is often the smarter starting point.

What a syndicated study actually is and what it is not

Syndicated research is sometimes associated with generic reports, rigid methodologies, and data that does not fully match the business question.

But that’s not what we mean by it at APLUSA. For us the definition is simple: A syndicated study collects data across a market or therapy area and makes it available to multiple buyers, instead of being built for a single client.

This has two important consequences.

First, the cost is shared, which makes the data far more accessible.

Second, because data has already been collected, teams can access existing findings far more quickly than if commissioning a new study. This provides an immediate foundation for understanding markets at scale, combining current data with historical back data to reveal not just what is happening now, but how markets have evolved over time. Older waves are often available at heavily discounted prices, making it cost-effective to build trend context and support forecasting without starting from scratch.

One important caveat: this refers to access to existing back data. Producing a fully tailored report with analysis and strategic interpretation still takes time, the advantage lies in removing the wait for new fieldwork, not in bypassing the analytical work.What it should not mean is generic output.

The difference depends on how the study is designed, how it is fielded, and how the analysis is delivered.

Five situations where syndicated research outperforms custom

Not every question should be answered with syndicated data. But in certain situations, it is consistently the better option.

1. When speed is non-negotiable

Launches, competitive shifts, and internal reviews do not wait. When teams need rapid access to existing market data on prescribing patterns, treatment dynamics, and competitive positioning, syndicated research is a viable path.

2. When you need market-level context

Internal data shows what is happening within your brand. Syndicated data shows what is happening around it, including prescribing behaviors, competitors, and treatment dynamics.

3. When internal resources are stretched

Custom studies require time to design, procure, and manage. Syndicated research reduces that burden and allows teams to focus on insight.

4. When multiple teams need the same answers

Commercial, medical, market access, and pipeline teams often ask similar questions. A shared dataset creates alignment and a common language across functions.

5. When you already have a data source and want to validate it

For teams that already have a trusted data source, the value of syndicated research lies in triangulation. A second, independent perspective, particularly from a premium provider like APLUSA, helps validate signals, challenge assumptions, and reduce the risk of decisions driven by a single methodology.

What a well-designed syndicated study looks like

These limitations are not inherent. They are design choices. Three factors determine whether a syndicated study delivers real value.

1. It is built with physicians, not just sent to them

There is a difference between surveying physicians and designing with them.

When studies are co-developed with specialists, the questions reflect real clinical practice, the frameworks align with decision making, and the outputs carry credibility across teams.

The result is not just valid data. It is clinically grounded insight.

2. It is available when you need it

Speed only matters if the data is truly accessible.

For teams working against tight internal deadlines, being able to access data from a study that has already been conducted, without initiating new fieldwork, without design phase and internal procurement cycles, can make a significant difference to what is possible.

For time-pressured teams, this often determines whether decisions are made with evidence or without it.

3. The reporting, analysis, and insights are fully customized to your priorities

A dataset alone is not insight.

A strong syndicated approach provides high-quality structured data and then delivers fully customized reporting, analysis, and strategic interpretation that is shaped around your specific indication, your competitive context, and the decisions your team actually needs to make.

This is the real distinction. The data may be shared. The reporting, analysis, and insights delivered to each client should not be.

The only question that really matters

Before choosing any research approach, ask a simple question: What decision does this need to support, and when does that decision need to be made?

If your answer includes a short timeline, a need for market context, cross-functional questions, and limited internal bandwidth, syndicated research is not a compromise. It is the right approach.

The only caveat is that not all syndicated studies are built with the same level of rigor, clinical grounding, or flexibility in analysis.

THERAPY INTELLIGENCE™ BY APLUSA

Built for exactly these situations

APLUSA’s Therapy Intelligence™ is a portfolio of syndicated studies across solide tumors, hematological malignancies​, immunology, dermocosmetics and emerging therapies, designed to address the limitations described above.

Each study is:

• Physician-led, co-designed with specialists to ensure clinical relevance
• Based on data that has already been collected
• Supported by analysis that adapts to your strategic questions and priorities

If your team is facing tight timelines or needs market-level visibility, this is not about buying another report.

It is about understanding whether the data you need already exists.